secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001161697-25-000099
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M
--------------------------------------------------------------------------------

- Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).
- Q4 gross margin 62.9% (+260 bps); full year 63.4% (+480 bps).
- Net loss improved to $1.6M (Q4) and $6.1M (full year); adjusted EBITDA loss narrowed.
- Cash $9.6M at Dec 31; Q4 cash flow positive $0.8M; 2025 guidance: revenue $38-39M, gross margin 61-63%, operational cash flow positive.
- Novel Therapies segment renamed Pharma Services and Clinical Trials (PST), effective Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169725000099/0001161697-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169725000099/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer